Core Viewpoint - Anika Therapeutics, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following the release of disappointing clinical trial results for its product Hyalofast [1][3]. Group 1: Investigation Details - The law firm Kirby McInerney LLP is leading the investigation into Anika Therapeutics [1]. - The investigation focuses on whether Anika and/or its senior management engaged in unlawful practices related to the company's securities [1]. Group 2: Clinical Trial Results - On July 30, 2025, Anika announced topline results from a clinical trial of Hyalofast, which is a resorbable hyaluronic acid scaffold for cartilage repair [3]. - The trial showed consistent improvements in treated patients compared to microfracture, but did not meet its pre-specified co-primary endpoints [3]. - Factors affecting the trial results included a higher dropout rate in the microfracture arm and missed visits during COVID, leading to missing data and a reduced evaluable sample size [3]. - Following the announcement, Anika's share price fell by $3.06, or approximately 27.42%, closing at $8.10 per share [3].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for allegedly making misleading statements regarding its initiatives and projects during the class period from July 23, 2025, to October 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Fiserv's 2025 guidance, disclosed in July 2025, was based on assumptions that were "objectively difficult to achieve" [2]. - Following the revelation of these assumptions, Fiserv's share price dropped by $55.57, approximately 44%, from $126.17 on October 28, 2025, to $70.60 on October 29, 2025 [2]. Group 2: Lead Plaintiff Process - Investors who acquired Fiserv securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, with courts typically appointing those with the largest financial loss [3]. - Lead plaintiffs have the authority to influence case strategy, settlement decisions, and allocation of settlement funds among class members [3]. Group 3: Contact Information - Investors who purchased or acquired Fiserv securities and wish to learn more about the investigation can contact Kirby McInerney LLP for further information [4].

Core Viewpoint - A class action lawsuit has been filed against Blue Owl Capital for failing to disclose significant liquidity issues and pressures on its asset base due to BDC redemptions during the specified class period [2][6]. Financial Performance - Blue Owl reported third-quarter financial results on October 30, 2025, with new capital commitments of $14 billion for the quarter and $57 billion over the last twelve months. Direct lending originations were $10.9 billion for the quarter and $46.8 billion over the last twelve months. However, fee-related earnings were only $376.2 million, missing consensus estimates, and performance revenue fell 33% year over year to $188,000 [3]. - Following the financial report, Blue Owl's share price dropped by $0.70, or approximately 4.23%, from $16.56 to $15.86 [3]. Merger Announcement - On November 5, 2025, Blue Owl Capital Corporation and Blue Owl Capital Corporation II announced a definitive merger agreement, stating that the merger would enhance liquidity for shareholders. The exchange ratio for shares will be based on the NAV per share and market price prior to the merger [4]. - The announcement led to a decline in Blue Owl's share price by $0.74, or approximately 4.72%, from $15.69 to $14.95 [4]. Redemption Issues - A Financial Times article on November 16, 2025, reported that Blue Owl had blocked redemptions in one of its private credit funds, potentially leading to significant losses for investors. Investors in OBCD II will lose the ability to redeem cash at the fund's NAV after the merger, trading their shares for Blue Owl Capital Corporation shares, which are trading about 20% below the fund's NAV [5]. - This news caused Blue Owl's share price to decline by $0.85, or approximately 5.8%, from $14.62 to $13.77 [5].

Group 1 - The law firm Kirby McInerney LLP is investigating TechTarget, Inc. for possible violations of federal securities laws or unlawful business practices by the company or its senior management [1] - On December 6, 2024, TechTarget announced that its previous financial statements should no longer be relied upon and would be restated due to identified errors, affecting financial statements related to Informa Tech Digital Businesses of Informa PLC [1] - Following the announcement, TechTarget's share price fell by $2.74, approximately 10.7%, from $25.54 on December 9, 2024, to close at $22.80 on December 10, 2024 [1] Group 2 - Investors who purchased or acquired TechTarget securities are encouraged to contact Kirby McInerney LLP for more information regarding the investigation and their rights [2] - Kirby McInerney LLP is a New York-based law firm specializing in securities, antitrust, whistleblower, and consumer litigation, with a history of recovering billions of dollars for shareholders in securities litigation [2]

Core Viewpoint - Klarna Group plc is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing Q3 2025 financial results that led to a significant drop in share price [1][3]. Group 1: Company Overview - Klarna launched its IPO in September 2025, selling 34,311,274 shares at a price of $40.00 per share [3]. - The company reported a substantial increase in the provision for credit losses in its Q3 2025 financial results [3]. Group 2: Financial Impact - Following the announcement of Q3 results, Klarna's share price fell by $3.25, or approximately 9.3%, from $34.88 on November 17, 2025, to close at $31.63 on November 18, 2025 [3].

Core Viewpoint - Kirby McInerney LLP is investigating potential violations of federal securities laws by Barnes & Noble Education, Inc. and its senior management, following a disclosure regarding a possible overstatement of accounts receivable [1][2]. Summary by Sections Investigation Details - On July 18, 2025, Barnes & Noble revealed that management identified issues related to the recording of digital sales costs, leading to a potential overstatement of up to $23.0 million in accounts receivable as of May 3, 2025 [2]. - Following this announcement, Barnes & Noble's share price fell by $2.36, approximately 21%, closing at $8.87 per share on July 21, 2025 [2]. Investor Actions - Investors who purchased or acquired Barnes & Noble securities and have relevant information are encouraged to contact Kirby McInerney LLP to discuss their rights or interests regarding the investigation at no cost [3]. Law Firm Background - Kirby McInerney LLP is a New York-based law firm specializing in securities, antitrust, whistleblower, and consumer litigation, with a history of recovering billions of dollars for shareholders in securities litigation [4].

Core Viewpoint - Stride, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements regarding its products and services, which has led to significant declines in its stock price [3][4][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Stride securities between October 22, 2024, and October 28, 2025, alleging that the company inflated enrollment numbers and cut staff costs beyond statutory limits [3]. - A complaint was filed by the Gallup-McKinley County Schools Board of Education against Stride, alleging fraud and deceptive practices, including retaining "ghost students" to secure state funding [4]. - Following the complaint, Stride's share price dropped by $18.60, approximately 11.7%, from $158.36 to $139.76 [4]. Group 2: Impact on Company Performance - On October 28, 2025, Stride announced that "poor customer experience" led to a significant drop in enrollments, estimating a loss of 10,000-15,000 students, which resulted in a muted outlook for the company [5]. - The announcement caused Stride's share price to plummet by $83.48, or approximately 54.4%, from $153.53 to $70.05 [5].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. by Kirby McInerney LLP on behalf of investors who acquired StubHub securities during its September 2025 IPO, alleging that the company failed to disclose significant financial issues that misled investors [1][2]. Summary by Sections Lawsuit Details - The lawsuit claims that StubHub did not disclose changes in payment timing to vendors, which adversely affected free cash flow, leading to materially misleading financial reports and IPO offering documents [2]. - Investors who suffered losses have until January 23, 2026, to request lead plaintiff appointment [2]. Financial Impact - StubHub reported a negative free cash flow of $4.6 million for Q3 2025, a 143% decrease from the previous year's positive free cash flow of $10.6 million [3]. - Following this earnings report, StubHub's stock price dropped by $3.95, or approximately 21.0%, from $18.82 to $14.87 per share [3]. - By November 24, 2025, StubHub's stock price fell to $12.01, nearly 50% below its IPO price of $23.50 per share [4].

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Paysafe Limited regarding possible violations of federal securities laws or unlawful business practices [1][3]. Financial Performance - On November 13, 2025, Paysafe reported its Q3 2025 financial results, which missed revenue and EPS estimates due to a last-minute client shutdown that resulted in a several-million-dollar write-down [3]. - Following the announcement, Paysafe's share price fell by $2.80, or approximately 27.6%, from $10.16 on November 12, 2025, to close at $7.36 on November 13, 2025 [3]. Legal Investigation - The investigation by Kirby McInerney LLP focuses on whether Paysafe and/or its senior management engaged in unlawful business practices [1]. - The law firm specializes in securities litigation and has a history of recovering billions of dollars for shareholders [6].

Core Viewpoint - Alvotech is under investigation by Kirby McInerney LLP for potential violations of federal securities laws following a significant decline in its stock price after receiving a complete response letter from the FDA regarding its biologics license application for AVT05 [1][2]. Company Summary - Alvotech (NASDAQ: ALVO) experienced a stock price drop of $2.62 per share, approximately 34.25%, from $7.65 on October 31, 2025, to $5.03 on November 3, 2025, after the FDA issued a complete response letter related to a failed facility inspection [1]. Legal Context - Kirby McInerney LLP is conducting an investigation on behalf of Alvotech investors concerning possible unlawful business practices by the company or its senior management [1][2]. - The law firm specializes in securities litigation and has a history of achieving recoveries totaling billions of dollars for shareholders [3].